Myelodysplastic/Myeloproliferative Neoplasms
- PMID: 32091773
- Bookshelf ID: NBK553956
- DOI: 10.1007/978-3-030-02278-5_75
Myelodysplastic/Myeloproliferative Neoplasms
Excerpt
The myelodysplastic syndrome-myeloproliferative neoplasms (MDS/MPNs) are a heterogeneous group of hematologic malignancies characterized by dysplastic and myeloproliferative clinical, laboratory, and morphological overlapping features, both in marrow and in blood.
Copyright 2019, EBMT and the Author(s).
Sections
References
-
- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. - PubMed
-
- Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018;93:277–85. - PubMed
-
- Chang TY, Dvorak CC, Loh ML. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood. 2014;124:2487–97. - PubMed
-
- Cseh A, Niemeyer CM, Yoshimi A, et al. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood. 2015;125:2311–3. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous